RE: Abstract from upcoming EAS conference in June I just looked over the final program for the ATVB 2013 conference once again. Although RVX is still not listed as presenting, I found these two very relevant poster titles.
181: BET Bromodomain Inhibition Suppresses Endothelial Inflammation and Atherosclerosis
Jonathan Brown, Qiong Duan, Gabriel Griffin, Brigham and Women's Hosp, Boston, MA; Ronald Paranal, Steven Bair, Dana Farber Cancer Inst, Boston, MA; Gail Newton, Andrew Lichtman, Brigham and Women's Hosp, Boston, MA; Andrew Kung, Columbia Univ, New York, NY; Francis Luscinskas, Brigham and Women's Hosp, Boston, MA; Tianlun Yang, Xiangya Hosp, Central South Univ, Changsha, China; Kevin Croce, Brigham and Women's Hosp, Boston, MA; James Bradner, Dana Farber Cancer Inst, Boston, MA; Jorge Plutzky, Brigham and Women's Hosp, Boston, MA
.
427: Apoliporotein A-I Improves Glucose Tolerance and Enhances Insulin-Dependent and Insulin-Independent Glucose Uptake in the db/db Mouse Model of Type 2 Diabetes
Blake J Cochran, Shudi Tang, Kerry-Anne Rye, Univ of New South Wales, Sydney, Australia
.
181 of course sounds very relevant. 427 is the same group that I had previously noted has an apoAI/diabetes abstract at the June EAS meeting.